Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis
- 1 July 2007
- Vol. 25 (29) , 5433-5440
- https://doi.org/10.1016/j.vaccine.2007.04.071
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A review of vaccine research and development: Meningococcal disease☆Vaccine, 2006
- Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: A model-based evaluationVaccine, 2006
- Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in SpainVaccine, 2005
- Dynamic Models of Meningococcal Carriage, Disease, and the Impact of Serogroup C Conjugate VaccinationAmerican Journal of Epidemiology, 2005
- Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal diseaseVaccine, 2004
- Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysisBMJ, 2003
- The EQ-5D and the Health Utilities Index for permanent sequelae after meningitisJournal of Clinical Epidemiology, 2002
- Influence of Serogroup on the Presentation, Course, and Outcome of Invasive Meningococcal Disease in Children in the Republic of Ireland, 1995–2000Clinical Infectious Diseases, 2002
- Complications of Meningococcal Disease in College StudentsClinical Infectious Diseases, 2001
- Mucosal Immune Responses to Meningococcal Group C Conjugate and Group A and C Polysaccharide Vaccines in AdolescentsInfection and Immunity, 2000